Precision immunosuppression in adult lung transplantation: are we there yet? - PubMed
6 hours ago
- #biomarkers
- #lung transplantation
- #precision immunosuppression
- Long-term outcomes in adult lung transplantation are limited by rejection, infection, and immunosuppressive toxicity.
- Conventional immunosuppression fails to account for individual variability in immune risk, drug metabolism, and complication susceptibility.
- Emerging biomarkers like Torque Teno virus (TTV) load, donor-derived cell-free DNA (dd-cfDNA), and tissue-bound donor-specific antibodies enable personalized immune management.
- Pharmacogenomic profiling and strategies like extracorporeal photopheresis support risk-adapted therapy.
- Integration of biomarkers from blood and bronchoalveolar lavage allows earlier detection of subclinical rejection and infection risk.
- Precision immunosuppression is transitioning to early clinical implementation, potentially enabling safer immunosuppression minimization and improved outcomes, though prospective validation is needed.